Huge Johnson & Johnson Acquisition Targets Robotics
On Wednesday, Johnson & Johnson announced that a subsidiary had entered a definitive agreement to acquire a robotic technology firm focused on lung cancer.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 108
What Held Back Teva in Q4
Teva released mixed fourth-quarter financial results before the markets opened on Wednesday and its shares pulled back.
Short Sellers Run for Cover From Major Biotechs
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The January 31 short interest data have been compared with the previous report, and short interest in most of the…
Why Gilead’s Pain Is Intercept’s Gain
It's another disappointing day for one of America's top biotech companies. But that may prove to be great news for Intercept Pharmaceuticals.
Major Pharma Scares Off Short Sellers
The January 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Tobacco Use Surges Among Young People, Triggered by E-Cigarettes
Around 4.9 million middle and high school students used tobacco in 2018. That is up from 3.6 million in 2017, a 36% increase. Virtually the entire increase was due to e-cigarette use. The Centers…
Alarming Trends on E-Cigarette Use Among High School and Middle School Students
It is supposed to be undeniable that smoking and using any forms of tobacco is bad for your health. And the rate of smoking cigarettes has been on the decline for years and years…
FTC, FDA Warn Makers of Alzheimer Cure Supplements
The U.S. FDA and the FTC have sent warning letters to three makers and distributors of products that make unsubstantiated claims of providing relief or cures from a variety of diseases, including Alzheimer's.
Major 2019 Biopharma Catalysts Coming in February and March
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February and March.
Is Solid Bio Done For After This Duchenne Muscular Dystrophy Trial?
Solid Bio shares were absolutely crushed on Thursday after preliminary data from the firm’s midstage trial in Duchenne muscular dystrophy was not up to par.
Can MacroGenics Keep Up the Pace After This Phase 3 Trial?
MacroGenics shares absolutely exploded on Wednesday after the firm announced late-stage results for its breast cancer trial.
Why Gilead’s Disappointment Is Not Just an Earnings Story
Gilead Sciences is living up to our theory that Big Biotech is now effectively the same as Big Pharma.
Merck Clears a Low Hurdle for Q4 Earnings
Merck released better-than-expected fourth-quarter financial results after the markets closed on Thursday.
What to Expect When Merck Reports on Friday
Merck is scheduled to release its fourth-quarter before the markets open on Friday, and analysts are looking for solid top and bottom line growth.
Why 6 Top Biotech Stocks Could Beat Wall Street Q4 Estimates
The biotech team at SunTrust feel that it would not be a major surprise to see these six top companies post quarterly results that beat top-line Wall Street expectations.